The combination of digoxin and GSK2606414 exerts synergistic anticancer activity against leukemia in vitro and in vivo

Xue Hong Zhang, Xin Yu Wang, Zhi Wei Zhou, Hua Bai, Lin Shi, Yin Xue Yang, Shu Feng Zhou, Xiao Chun Zhang

Research output: Contribution to journalArticlepeer-review

Abstract

Digoxin is a member of cardiac glycosides and recent studies show that digoxin plays anticancer role in several types of cancer. However, the anticancer effects and mechanism of digoxin in leukemia is largely unknown. Her, our data show that digoxin treatment significantly inhibits leukemia cell viability. In addition, digoxin treatment significantly induced apoptosis and G2/M cell cycle arrest in leukemia cells. Furthermore, we demonstrated that digoxin treatment inactivate that oncogenic pathway Akt/mTOR signaling in leukemia cells. In addition, our data show that digoxin treatment induces activation of unfolded protein response (UPR) signaling in leukemia cells. Interestingly, our in vitro and in vivo experiments show that combination treatment of digoxin and UPR inhibitor can synergistically suppress leukemia growth and induces apoptosis and cell cycle arrest compared to single drug treatment. In summary, our findings indicate that digoxin has potential anticancer effects on leukemia. The combination of digoxin and UPR signaling inhibitor can exerts synergistic anticancer activity against leukemia.

Original languageEnglish (US)
Pages (from-to)812-820
Number of pages9
JournalBioFactors
Volume43
Issue number6
DOIs
StatePublished - Nov 1 2017

Keywords

  • anticancer activity
  • digoxin
  • leukemia
  • UPR signaling inhibitor

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Clinical Biochemistry

Fingerprint

Dive into the research topics of 'The combination of digoxin and GSK2606414 exerts synergistic anticancer activity against leukemia in vitro and in vivo'. Together they form a unique fingerprint.

Cite this